drugset
drugset / Trial / NCT01518894

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

NCT01518894 ↗

Phase 1 Completed 30 enrolled Biogen
RandomizedParallel-groupDouble-blindBasic science

Summary

To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.

Timeline

Start
2011-11
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.1 mg Oral
Subject PESAMPATOR Small molecule 0.2 mg Oral

Indications

schizophrenia